Syngene reported Q1 FY26 revenue of ₹874 Cr (+11% YoY) and PAT of ₹87 Cr (+67% YoY). Not bad for India’s first CRO, but investors are still nursing a -28% 1Y stock return. With a P/E of 53, ROE at 10%, and EV/EBITDA at 23x, this feels less like “value discovery” and more like paying rent for Biocon’s basement.
2. Introduction
Founded in 1993 as Biocon’s in-house research wing, Syngene has since become the poster child for CRAMS (Contract Research and Manufacturing Services) in India. If Biocon is the Bollywood hero, Syngene is the sidekick — always in the frame, doing the heavy lifting, but rarely stealing the limelight.
It now runs a 1.9 million sq. ft. scientific Disneyland across Bangalore, Mangalore, and Hyderabad. With 400+ active clients including Amgen, J&J, Merck, Bayer, and Unilever, it basically rents out scientists the way OYO rents out hotel rooms.
The catch? While it brags about a 6,000+ scientist army, the returns don’t look like Nobel Prize work. Revenues grew at 12% CAGR, profits at ~6%, but the stock trades at Silicon Valley multiples. Either investors are on drugs (pun intended) or Syngene’s future pipeline better cure more than diseases — maybe cure overvaluation too.
3. Business Model – WTF Do They Even Do?
Think of Syngene as the Uber for pharma R&D — you bring the molecule, they provide the lab, scientists, and compliance headaches.
Discovery Services: Full-time equivalent (FTE) model. Big pharma rents Indian scientists by the dozen.
Development Services: Fee-for-service (FFS). Pre-clinical and clinical trial support. Basically, pharma’s tuition classes.
Manufacturing Services: API, biologics, fill-finish. Like moving from cooking samples to running a catering business.
Dedicated R&D Centers: For Amgen, Baxter, and Bristol Myers Squibb. Long-term 5–10 year contracts that look like shaadi arrangements.
The sweetener? Regulatory accreditations galore — USFDA, EMA, PMDA. In an industry where one 483 letter can tank valuations, this is Syngene’s bulletproof vest.
4. Financials Overview
Q1 FY26 vs Q1 FY25 vs Q4 FY25
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
874
790
1,018
10.7%
-14.2%
EBITDA
206
170
344
21.2%
-40.1%
PAT
86.7
76.0
183
14.1%
-52.6%
EPS (₹)
2.15
1.88
4.55
14.4%
-52.7%
Commentary: YoY growth is healthy, but QoQ Syngene looks like it just came back from a failed clinical trial. EPS halved QoQ — good luck explaining that in analyst calls.
5. Valuation Discussion – Fair Value Range Only
P/E Method: EPS (TTM) ₹12.6 × industry average P/E (50.7) → ₹640. Current CMP ₹664 = fair-ish.
EV/EBITDA: EV = ₹26,570 Cr; EBITDA = ₹1,078 Cr. EV/EBITDA = 23.1 vs global CRO average ~18–20x.
Disclaimer: For educational purposes only, not investment advice.
6. What’s Cooking – News, Triggers, Drama
Stelis Biopharma deal: Acquired biologics manufacturing facility (20k litre capacity + fill-finish). Finally, some capex that isn’t just lab coats.
US biologics expansion: Bought a US facility from Emergent BioSolutions in 2025. Syngene is officially exporting not just drugs, but also capex headaches.
Contracts: BMS contract extended till 2030, Amgen getting a
